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Abstract
Objective: To validate and develop an immunonephelometric assay for the determination of alpha-1 antitrypsin 
(AAT) levels in dried blood spots from COPD patients in Brazil. Methods: We determined AAT levels in serum 
samples and dried blood spots from 192 COPD patients. For the preparation of dried blood spots, a disk (diameter, 
6 mm) was placed into a tube, eluted with 200 µL of PBS, and stored overnight at 4°C. All of the samples were 
analyzed by immunonephelometry in duplicate. We used the bootstrap resampling method in order to determine 
a cut-off point for AAT levels in dried blood spots. Results: The correlation coefficient between the AAT levels 
in serum samples and those in dried blood spots was r = 0.45. For dried blood spots, the cut-off value was 2.02 
mg/dL (97% CI: 1.45-2.64 mg/dL), with a sensitivity, specificity, positive predictive value, and negative predictive 
value of 100%, 95.7%, 27.2%, and 100%, respectively. Conclusions: This method for the determination of AAT 
levels in dried blood spots appears to be a reliable screening tool for patients with AAT deficiency. 
Keywords: alpha 1-antitrypsin deficiency; Nephelometry and turbidimetry; Pulmonary disease, chronic obstructive.
Resumo
Objetivo: Validar e desenvolver um método de dosagem de alfa-1 antitripsina (AAT) por imunonefelometria em 
amostras de sangue em papel-filtro em pacientes com DPOC no Brasil. Métodos: Amostras de soro e de sangue 
em papel-filtro de 192 pacientes com DPOC foram utilizadas para a dosagem de AAT. Para a preparação das 
amostras de sangue em papel-filtro, um disco do papel com diâmetro de 6 mm foi colocado em um tubo e eluído 
com 200 µL de PBS, permanecendo por toda a noite a 4°C. Todas as amostras foram analisadas em duplicata 
por imunonefelometria. O método de reamostragem bootstrap foi utilizado para a determinação de um ponto 
de corte para o nível de AAT nas amostras de sangue em papel-filtro. Resultados: O coeficiente de correlação 
entre os níveis de AAT em soro e em sangue em papel-filtro foi de r = 0,45. Para as amostras em papel-filtro, o 
ponto de corte foi de 2,02 mg/dL (IC97%: 1,45-2,64 mg/dL), com sensibilidade, especificidade, valor preditivo 
positivo e valor preditivo negativo de 100%, 95,7%, 27,2% e 100%, respectivamente. Conclusões: Este método 
de determinação dos níveis de AAT em sangue em papel-filtro se mostrou uma ferramenta confiável para o 
rastreamento de pacientes com deficiência de AAT. 
Descritores: Deficiência de alfa 1-antitripsina; Nefelometria e turbidimetria; Doença pulmonar 
obstrutiva crônica.
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method for the determination of AAT levels has 
been developed, and few laboratories can determine 
serum AAT levels. Considering the landmass of 
Brazil, it is important that a dried blood spot 
method be implemented in the country.
Therefore, the objective of the present study was 
to develop and validate an immunonephelometric 
assay for the determination of AAT levels in 
dried blood spots from COPD patients in Brazil.
Methods
This was a cross-sectional study evaluating 
COPD patients recruited from the COPD Outpatient 
Clinic of the Federal University of São Paulo 
Pulmonary Rehabilitation Center between July 
and September of 2011.
The inclusion criteria were as follows: having 
been diagnosed with COPD in accordance with the 
criteria established by the European Respiratory 
Society—i.e., having an FEV1/FVC less than 88% 
predicted (males) or less than 89% predicted 
(females) after bronchodilator use(16); having been 
clinically stable in the last six weeks(17); and being 
40 years of age or older. Patients with a previous 
diagnosis of AAT deficiency were excluded from 
the study, as were those with clinical symptoms 
of asthma and those with any non-pulmonary 
inflammatory or infectious process leading to 
increased serum AAT concentrations.
All patients gave written informed consent. 
The determination of AAT levels was performed at 
the Centro de Diagnóstico Brasil (Brazil Diagnostic 
Center), located in the city of São Paulo. The 
present study was approved by the Research 
Ethics Committee of the Federal University of São 
Paulo Hospital São Paulo (Protocol no. 0633/10).
All study participants had recently undergone 
spirometry (less than one year previously) with 
a portable spirometer (Easy One®; NDD Medical 
Technologies, Chelmsford, MA, USA, and Zurich, 
Switzerland). The reference values used to calculate 
percentage of predicted values were based on 
the reference standards of the Third National 
Health and Nutrition Examination Survey.(18)
After analysis of the spirometry results and 
application of the inclusion and exclusion criteria, 
the patients underwent blood sample collection 
using two methods: blood was drawn from the 
cubital vein into a tube containing EDTA and 
centrifuged at 3,200 rpm for 30 min, with the 
serum being separated and stored at −20°C; 
and a drop of peripheral blood, obtained by 
Introduction
Alpha-1 antitrypsin (AAT) deficiency is an 
autosomal codominant genetic disorder resulting 
from mutations in the SERPINA1 gene, which 
encodes the synthesis of the AAT protein.(1) It is 
characterized by a reduction in circulating plasma 
AAT levels and is associated with an increased 
risk for early pulmonary emphysema,(2) as well 
as for liver disease and panniculitis.(3)
Once considered a rare disease, AAT deficiency 
is a highly prevalent genetic condition, according 
to current epidemiological data, although it is 
frequently underdiagnosed in clinical practice.
(3-5) Estimates from studies conducted in eight 
countries (Canada, the Netherlands, Spain, the 
United Kingdom, Sweden, New Zealand, and 
Australia) show that only 0.41% and 0.35% of 
individuals with the PiZZ phenotype and the SS 
phenotype, respectively, had been identified.(6) In 
Brazil, there are no epidemiological data on the 
prevalence of AAT deficiency or the frequency 
of deficiency alleles.(7)
Recent recommendations from the World 
Health Organization, the American Thoracic 
Society, and the European Respiratory Society 
advocate the use of assays for the quantitative 
determination of plasma AAT concentrations, 
especially in patients with COPD, liver disease 
of unknown etiology, necrotizing panniculitis, 
bronchiectasis of unknown etiology, or a family 
history of liver disease, necrotizing panniculitis, 
COPD, and bronchiectasis.(8,9) Early diagnosis is 
essential to the prognosis of individuals with 
AAT deficiency, given that the natural history 
of pulmonary involvement is directly affected 
by potentially modifiable environmental factors, 
such as smoking.(10,11)
The diagnosis of AAT deficiency is based on 
the quantitative determination of serum AAT 
levels, as well as on phenotyping, genotyping, 
or both.(12,13) One of the problems for conducting 
screening programs is that of blood handling 
and transportation. The implementation of a 
dried blood spot method would make it possible 
to use it in population programs, because it is 
a minimally invasive method, sample storage is 
easy, and it allows sample transportation from 
different regions to the central laboratory, with no 
need for complex and costly methods of sample 
preservation.(9,14) In addition, these samples can 
also be used for phenotyping and genotyping, 
if necessary.(13,15) In Brazil, no dried blood spot 
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blood spots contain much lower serum levels, 
making dilution unnecessary (1:1), as reported 
in previous studies.(19,20)
The statistical analysis was performed with 
the Statistical Package for the Social Sciences, 
version 18.0 for Windows (SPSS Inc, Chicago, 
IL, USA). Continuous variables are expressed as 
mean and standard deviation, and categorical 
variables are expressed as percentage. Pearson’s 
correlation coefficient was used to investigate 
the association between two parametric variables, 
namely, serum AAT values obtained in duplicate, 
AAT values in eluates, measured in duplicate; 
and serum AAT values relative to AAT values 
in eluates.
We used the bootstrap resampling method 
in order to determine a cut-off point and a 
confidence interval of 97% for dried blood 
spots. This method consists of a resampling 
technique, through which data from the actual 
sample (the study sample) are randomly selected 
(with N – 1) for observation and confidence 
intervals are generated for each calculated 
value. The sample is randomly selected 1,000 
times, and 1,000 models are made for each 
of these N – 1 samples, increasing the power 
of the sample in cases of small samples and 
improving the estimators of confidence when 
the sample distribution is unknown or when 
the population distribution is unknown. The 
cut-off point for dried blood spots was also 
characterized in terms of sensitivity, specificity, 
positive predictive value (PPV), and negative 
predictive value (NPV).
pricking the distal region of one of the fingers, 
was placed on a filter paper card (Whatman 903, 
lot W101; Whatman/GE Healthcare, Florham 
Park, NJ, USA); the filter paper card was dried 
in room air for 12 h and then stored at −20°C 
until the time of analysis.(19)
For the analysis of dried blood spots, the 
filter paper cards were cut into disks (diameter, 
6 mm) and the disks were placed into Eppendorf 
tubes, to which 200 µL of PBS were added. This 
solution remained at 4°C for 12 h overnight. On 
the following day, the disks were removed from 
the solution and, subsequently, the samples 
were centrifuged at 3,200 rpm for 30 min in 
order to separate the disk residues (solid part) 
from the liquid part of the samples, which 
is called eluate. The serum was thawed and 
centrifuged at 3,200 rpm for 30 min. Serum 
and eluate samples were analyzed on a Siemens 
BNII system (Siemens Healthcare, Indianapolis, 
IN, USA).
The system was calibrated with the N 
Protein Standard SL (Nephelometry; Siemens 
Healthcare). The calibration curves were tested 
at different dilutions (1:160; 1:80; 1:40; 1:20; 
1:10; and 1:5). The margin of deviation from 
the standard protein and the value obtained 
were accepted within a range of +5 to −5. In 
addition, daily checks with the standard SL were 
carried out at different AAT concentrations: 
low (101.0 mg/dL); medium (159.0 mg/dL); 
and high (231.0 mg/dL).
The analysis of AAT concentrations was 
performed using the N-antiserum, which is a 
liquid animal serum produced by immunization 
of rabbits with highly purified human AAT 
(Siemens Healthcare).
Eluate and serum samples were placed 
into 5-mL acrylic tubes and analyzed by 
immunonephelometry. This method is 
characterized by the emission of an intense 
beam of light over a sample containing immune 
complexes between the AAT protein and anti-AAT 
antibodies. The beam of light, upon contact 
with this immune complex, is reflected and 
collected by a photometer, the intensity of 
the reflected radiation being proportional to 
the amount of antigen-antibody present in 
the sample. Serum samples are automatically 
diluted by the system at a ratio of 1:20, 
which is the concentration required to achieve 
antigen-antibody equilibrium. However, dried 
Figure 1 - Correlation between the duplicate 
measurements of serum alpha-1 antitrypsin (AAT) 
levels (N = 192).
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The spirometry results are described in 
Table 1, and, as expected for COPD patients, 
the values for percentage of predicted FEV1/FVC 
and percentage of predicted FEV1 characterized 
obstructive lung disease.
To test sample reproducibility, AAT levels 
in serum and in eluates from dried blood spots 
were determined in duplicate. Figure 1 shows the 
correlation between the duplicate measurements 
of serum AAT levels (r = 0.98), and Figure 2A 
shows the correlation between the duplicate 
measurements of AAT levels in eluates from dried 
blood spots (r = 0.52).
Some eluate samples were turbid in one 
of the duplicate measurements performed, 
affecting the AAT value obtained and causing 
disparity between the duplicate measurements 
of the same sample. Therefore, we performed 
a second correlation analysis of the duplicate 
measurement results of eluates from dried blood 
spot samples that were not turbid (n = 116). 
The second analysis showed a correlation of r 
= 0.84 (Figure 2B). However, none of the three 
patients with AAT deficiency, as determined 
by the measurement of serum AAT levels, a 
method considered to be the gold standard, 
were included in this analysis, because one of 
the duplicate samples was turbid.
For the analysis of correlation between the 
serum AAT levels and the AAT levels in eluates 
from dried blood spots, we selected one of the 
serum AAT values and one of the AAT values in 
eluate samples that were not turbid. The observed 
correlation was r = 0.45 (Figure 3).
Results
A total of 240 patients were contacted over 
the three-month study period. However, only 
192 patients met the eligibility criteria. Of 
the 48 individuals who were excluded, 17 had 
exacerbations, 18 did not meet the spirometry 
criteria for COPD, 5 showed a bronchodilator 
response and had a history consistent with 
asthma, 3 had bronchiectasis, 2 had pulmonary 
sarcoidosis, 2 had lung cancer, and 1 had sequelae 
of pulmonary tuberculosis.
The demographic data of the study participants 
are described in Table 1. There were no significant 
gender-related differences. The mean age of 
the study population was 68.5 ± 9.6 years. The 
individuals were predominantly White.
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Figure 2 - In A, correlation between the duplicate measurements of alpha-1 antitrypsin (AAT) levels in 
eluates from dried blood spots (N = 192). In B, correlation between the duplicate measurements of AAT 
levels in eluates from dried blood spot samples that were not turbid (n = 116).
A B
Figure 3 - Correlation between the measurements 
of serum alpha-1 antitrypsin (AAT) levels and the 
measurements of AAT levels in eluates from dried 
blood spots (n = 192).
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deficiency in 3 patients. However, with the value 
of 2.64 mg/dL, 32 patients would have to undergo 
determination of serum AAT levels for establishing 
this diagnosis also in 3 patients.
Discussion
The objective of the present study was to 
develop and validate an immunonephelometric 
assay for the determination of AAT levels in eluates 
from dried blood spots in patients with COPD. 
We chose to create a confidence interval starting 
at the cut-off point determined by the bootstrap 
resampling method, evaluating the sensitivity 
and specificity of the values and their effect 
on clinical choices for screening new patients.
The quantitative determination of serum 
AAT levels is recommended for the diagnosis 
of AAT deficiency.(9) However, this test in not 
performed in most Brazilian cities; handling, 
storage, transportation, and costs make its large-
scale use unfeasible. Therefore, analysis of dried 
blood spots by immunonephelometry becomes 
an attractive option in terms of accessibility,(21) 
given that the samples can be mailed to a central 
laboratory from anywhere in Brazil.(22) In the 
present study, the dried blood spot samples were 
frozen at −20°C, because they were not analyzed 
immediately after collection. However, dried 
blood spot samples can be maintained in room 
air for one week, as well as in temperatures of 
4°C and −20°C for four weeks.(19)
The results of duplicate measurements of 
serum AAT levels were highly reproducible (r = 
0.98), which shows excellent sample stability. The 
correlation between the serum AAT levels and 
the AAT levels in dried blood spots was low (r = 
0.45), suggesting that the AAT values measured 
in dried blood spots cannot be quantitatively 
compared with those measured in serum. This 
finding differs from those reported by some authors, 
who observed a good correlation between the 
determination of AAT levels in dried blood spots 
and the determination of serum AAT levels. Wencker 
et al. validated an immunonephelometric assay 
in 427 patients with lung disease and found an 
excellent correlation between the values measured 
in dried blood spots and those measured in serum 
(r = 0.95), with no false-negative or false-positive 
results.(22) The findings corroborate those of Costa 
et al., who obtained a good correlation between 
500 serum and dried blood spot samples (r2 
= 0.86).(19) However, those authors emphasize 
To determine the sensitivity and specificity 
of the eluate method, we used the bootstrap 
resampling method, comparing the AAT values 
measured in serum (gold standard) with those 
measured in eluates from dried blood spots, so 
as to determine a cut-off point for AAT values 
in eluates; the value obtained was 2.02 mg/dL 
(97% CI: 1.45-2.64). The values for sensitivity, 
specificity, PPV, and NPV of the AAT values in 
eluates from dried blood spots are shown in 
Table 2. All three patients with AAT deficiency 
in our sample had AAT levels below 1.80 mg/
dL (62.6 mg/dL in serum); the two values (2.02 
mg/dL and 2.64 mg/dL) had a sensitivity and 
NPV of 100%. With the cut-off point of 2.02 
mg/dL, 14 of the 192 patients in our sample 
would have to undergo determination of serum 
AAT levels for establishing the diagnosis of AAT 
Characteristic Result
Gender
Female 105 (54.7)
Male 87 (45.3)
Age, yearsb 65.8 ± 9.6
Race
White 157 (81.8)
Non-White 35 (18.2)
Spirometryb
Absolute FEV1/FVC 0.47 ± 0.10
FEV1/FVC, % of predicted 62.4 ± 14.4
FVC, L 2.64 ± 0.77
FVC, % of predicted 82.4 ± 19.9
FEV1, L
 1.27 ± 0.72
FEV1, % of predicted
 51.4 ± 18.9
Table 1 - Demographic characteristics of the sample 
(N = 192).a
aValues expressed as n (%), except where otherwise 
indicated. bValues expressed as mean ± SD.
Variable Cut-off point
Obtained Minimuma Maximuma
2.02 1.45 2.64
Sensitivity 100.0% 66.6% 100.0%
Specificity 95.7% 98.9% 86.7%
Positive 
predictive value
27.2% 50.0% 10.7%
Negative 
predictive value
100.0% 99.4% 100.0%
Table 2 - Sensitivity, specificity, positive predictive 
value, and negative predictive value of cut-off points 
calculated by using the bootstrap resampling technique.a
aAt the 97% CI.
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can be detected will result in a larger number 
of false-positive results. The disadvantage of 
false-positive results in the detection of AAT 
deficiency is evident, because a larger number of 
serum tests will be conducted.(24) However, it must 
be borne in mind that the process of screening 
new patients for AAT deficiency should begin 
with screening tests rather than end with them.
Regarding the cut-off point for dried blood spots 
for screening patients for AAT deficiency, we found 
two studies in the literature that have reported 
different values. One study, which evaluated 300 
patients with COPD and 200 healthy individuals, 
observed that all patients with AAT deficiency 
had values below 1.8 mg/dL in dried blood spots, 
which was equivalent to a serum concentration 
of 100 mg/dL.(19) After that study, two groups of 
authors adopted the same cut-off point as that 
suggested by Costa et al.(19) and found that dry 
blood spot tests produced no false-positive or 
false-negative results when compared with genetic 
tests, showing that the value established in that 
study was highly accurate.(15,22) In 2006, Gorrini 
et al. evaluated 114 patients and established a 
cut-off point of 1.13 g/L for dried blood spots, 
with a sensitivity and specificity of 0.92 and 
0.90, respectively.(20) These values are similar to 
those reported in the present study; however, 
the cut-off point stipulated in the present study 
was considerably higher, because we decided to 
adopt a sensitivity of 100%, greatly reducing the 
possibility of false-negative results.
The immunonephelometric assay for the 
determination of AAT levels in dried blood spots 
that was developed in the present study showed 
a moderate correlation (r = 0.54) between the 
duplicate measurements of the same sample. 
However, some samples were turbid in one 
of the duplicate measurements, a factor that 
reduces light reflection at the time of analysis 
and consequently reduces AAT levels, which 
could have directly affected the correlation of 
the duplicate dried blood spots. A sub-analysis 
only of the duplicate measurements of samples 
that were not turbid revealed a good correlation 
(r = 0.84). This sub-analysis did not include any 
patients with AAT deficiency, which means that 
this finding may not be representative for the 
population of individuals with AAT deficiency. 
There are no published studies in the literature 
that have addressed the reproducibility between 
serum samples and dried blood spots or the effect 
that, although the two techniques have a good 
correlation, the dried blood spot method is a semi-
quantitative rather than a quantitative method, 
being appropriate for screening, on the basis of a 
cut-off point, providing positive or negative results 
for the presence of the AAT protein. One group 
of Italian researchers also validated a dried blood 
spot method in comparison with the standard 
serum method in 149 patients who had low or 
very low serum AAT levels (0.16-0.53 g/L) and in 
individuals who had intermediate or normal AAT 
levels (0.54-2.93 g/L). The correlation coefficients 
of the two groups were r2 = 0.98 and r2 = 0.90, 
respectively.(20) However, those authors did not 
analyze their results in terms of PPV or NPV for 
the evaluation of sensitivity and specificity.
The fact that there is recognized variation in 
immunonephelometric assays led us to calculate a 
confidence interval, obtaining the minimum and 
maximum values in relation to the cut-off point. 
To determine this interval, we used the bootstrap 
resampling method, because the population of 
individuals with AAT deficiency was small. This 
analysis made it possible to increase the sample 
power, because the calculation was repeated 
1,000 times, establishing a cut-off point of 
2.02 mg/dL and making the 97% confidence 
interval more accurate (1.45-2.64 mg/dL). On 
the basis of these results, we evaluated the 
sensitivity, specificity, PPV, and NPV of the 
cut-off point established through this type of 
sampling (Table 2). For the cut-off point of 
2.02 mg/dL obtained for dried blood spots, 
we found a sensitivity and specificity of 100% 
and 95.7%, respectively, with a PPV and NPV 
of 27.2% and 100%, respectively. By using the 
maximum value in the confidence interval, it 
is possible that no patient with AAT deficiency 
will be identified as normal. After a detailed 
review of the literature, we found no studies 
reporting confidence interval values for AAT 
levels in dried blood spots.
To Kwon & Farrell, screening tests should 
be highly sensitive, because this characteristic 
reduces the probability of an individual having 
a false-negative result. False-negative results are 
the major concern in screening tests, because 
individuals will probably be identified only when 
they start having symptoms, which sometimes 
occurs late in the disease, compromising prognosis.
(23) Conversely, the establishment of a higher 
cut-off point so that all cases with deficiency 
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